新闻 总部

沃芬发布2018年年报

沃芬持续增长


西班牙,巴塞罗那 - 2019/05/05

沃芬持续增长

  • 营业收入同比增长5.3%,达13.59亿欧元(约合人民币101.84亿元);营业利润增长13.2%
  • 总部位于西班牙巴塞罗那,产品和服务覆盖全球100多个国家和地区
  • 在总裁Marc Rubiralta的领导下,沃芬着眼于长期发展,2018年研发投入达9300万欧元(约合人民币6.98亿元)
  • Luis Cantarell作为独立董事加入沃芬董事会

(2019年4月26日,巴塞罗那),沃芬发布2018年度年报。沃芬2018年度营业收入达13.59亿欧元(约合人民币101.84亿元),同比增长5.3%。以患者为中心,为医院和临床实验室提供创新解决方案,沃芬旨在为提升医疗水平贡献最大的价值。

沃芬继续加强其在体外诊断(IVD(1))行业的地位,销售额增长6.5%。北美地区的增长为6.5%;紧随其后的是亚太地区和拉丁美洲地区,增长均为6.2%。北美地区是沃芬最主要且最具竞争力的市场之一,目前占公司总销售额的26%,雇员人数(包括研发和制造)占公司的42%。西欧仍然是沃芬最大的市场,占其总销售额的42%。中国、拉丁美洲和EEMEAI(东欧、中东、非洲和印度)是预计未来增长最快的地区。

沃芬2018年度合并净利润达1.61亿欧元(约合人民币7.50亿元),略高于上一年,而EBITDA(未计利息、税项、折旧及摊销前利润)超过3.01亿欧元(约合人民币22.58亿元),比2017年增长6%。此外,营业利润达2.05亿欧元,同比增长13.2%。

在2018年,沃芬的主要业务领域均表现出良好的增长势头。凝血领域(2)增长4.7%;急症诊断(3)业务线在完成了最新收购的整合后,增长达8.3%;自身免疫(4)的增长达9.2%。

2016年,沃芬收购Tem (床旁患者血液管理的专业公司)。2017年,沃芬收购Accriva Diagnostics(专注于手术室和重症监护室床旁凝血检测(5)的领导企业)。2018年,沃芬成功完成了对Tem和Accriva Diagnostics的整合。从而,沃芬急症诊断业务拥有了更广泛的产品组合,能够为急诊、创伤科、手术室以及医院其他领域提供全面的解决方案。

继续加强管理,持续投入研发

Marc Rubiralta于今年1月担任沃芬总裁一职,他决心坚持Rubiralta Giralt家族对公司的承诺与发展。基于此,拥有丰富行业经验的Luis Cantarell加入沃芬董事会,担任独立董事。Luis Cantarell将在全球市场和医疗保健的各个领域贡献自己的专业经验。

沃芬确信,当下的研发是保证未来发展的关键因素。2018年沃芬研发投入达9300万欧元(约合人民币6.98亿元)。

谈及公司未来的规划,总裁Marc Rubiralta说:“在沃芬,我们始终以患者为中心,致力于为整个社会创造更大价值。因此,我们坚持研发投入,让创新引领我们走向未来。”位于巴塞罗那的Biokit新技术中心就是最好的范例,技术中心现已完成全面搬迁,正在全力运转中。

沃芬其他重要研发和生产中心位于贝德福德(美国马萨诸塞州),圣地亚哥(美国加利福尼亚州),奥兰治堡(美国纽约州),慕尼黑(德国)和巴塞罗那(西班牙)

2018年的新产品和2019年的优先事项

2018年,沃芬众多新产品面世,旨在为医务人员提供高质量的信息,并提高医疗系统的效率。在中国,沃芬隆重推出ACL TOP家族50系列产品,实现分析前样本质量管理。同时,沃芬在全球范围内推出了具有远程支持预警系统的ProDx。在美国、部分亚洲和欧洲市场,急症诊断产品线推出新一代血气分析仪GEM Premier 5000,用于检测患有代谢和/或呼吸系统疾病的重症及慢性患者。此外,VerifyNow在欧洲发布,用以辅助心血管和神经系统手术。在自身免疫领域,QUANTA-Lyser 3000系统进一步加强自身免疫诊断自动化进程。美国监管机构(食品和药品管理局)批准QUANTA Flash HMGCR标记物用于辅助诊断特发性炎性肌病,以及QUANTA Flash钙卫蛋白标记物辅助诊断胃肠疾病,如溃疡性结肠炎和克罗恩病。

所有这些创新都反映在沃芬的发展中。正如沃芬CEO Carlos Pascual所说,“近年来,沃芬的发展相当出色,这不单指我们稳健的财务表现。我们拥有5000 多名德才兼备的员工,我们对创新和价值持续关注,这些都是沃芬发展的基础,让沃芬与众不同。”基于这些宝贵的资产,我们对沃芬未来的发展充满希望。

2019年,沃芬公司的目标包括:进一步加强沃芬在其主要业务领域——凝血、急症诊断和自身免疫的领导者地位;进一步壮大在中国的业务;以及促进拉丁美洲,亚太地区和EEMEAI(东欧、中东、非洲及印度)等新兴市场的发展。

关于沃芬

沃芬是体外诊断的全球领导者之一,总部位于西班牙巴塞罗那。其在体外诊断领域的主要公司包括Instrumentation Laboratory(业务领域:凝血、急症诊断),Inova Diagnostics(业务领域:自身免疫),Biokit(业务领域:代工试剂(6)、生物材料(7),传染病血清学,临床化学和临床软件)。每一天,全球有超过150万个标本正在被沃芬的仪器和试剂检测,150万名患者因此受益。

此外,沃芬通过旗下Leventon公司(专注于输液治疗(8))制造医疗设备,并通过Izasa向西班牙、葡萄牙及欧盟其他地区进行医疗及科学仪器的分销。

沃芬在30多个国家和地区设有分支机构,并通过分销渠道向100多个国家和地区提供优质的产品和服务。

如需了解更多信息,请访问:www.werfen.com/cn


(1) In Vitro Diagnostics (IVD): Non-invasive tests performed on biological samples, usually blood, to diagnose, monitor, or rule out a disease.
(2) Hemostasis: Hemostasis disorders occur when blood loses its usual liquidity and can result in hemorrhage or the formation of clots.
(3) Acute Care Diagnostics: The specialized treatment of life-threatening conditions requiring rapid and comprehensive medical attention and frequent monitoring, usually in intensive care units, emergency rooms, and operating theaters.
(4) Autoimmunity: Autoimmune diseases occur when the body's immune system fails to distinguish between normal body tissue and antigens, resulting in an immune response that destroys healthy tissues. Autoimmune diseases include rheumatoid arthritis, lupus erythematosus, celiac disease, and Crohn’s disease, among others.
(5) Point-of-care testing (POCT): POCT is defined as medical tests at or near the point of patient care.
(6) Reagents: A substance or a compound added to a system to cause a chemical reaction. Reagents are often used to indicate the presence of another substance.
(7) Biomaterials: Any substance of biological origin (usually proteins) that has been designed, produced, and purified to function as the main raw material on an IVD test.
(8) Infusion Therapy: The administration of drugs directly into a vein through a needle or catheter.

Legal notice
This document contains forward-looking statements about our business, financial data, and events related to the prospects of Werfen. These forecasts can be identified by the use of words such as “expectation”, “vision”, “anticipation”, “intention”, “plan”, “belief”, “search”, “estimate”, “future”, “project”, or words with a similar meaning. We may also make projections in other reports, presentations, and press releases. Furthermore, our sales representatives may occasionally make forward-looking statements. These projections are based on our current expectations and on certain hypotheses, many of which are beyond the corporation’s control and subject to a series of risks and uncertainties. In the event that any of these risks or uncertainties should materialize or the underlying expectations are not fulfilled, the results or performance of Werfen may differ substantially (either positively or negatively) from those explicitly or implicitly forecast. Werfen assumes no obligation to update or revise any forward-looking statements made previously.

媒体联系
(中国)                                               
孙馨
电话:010-59756055
邮箱:sxin@werfen.com


(非中国地区)                                               
Gloria Maltas
电话:93-401-01-01
邮箱:gmaltas.werfen.com

 

附录

 

 

联系我们


留下您的联系方式。

电话: +86-10-5975-6055

Data protection policy
DATA PROTECTION POLICY: In application of the Personal Data Protection regulations, we inform that your personal data will be incorporated and processed in a file under the responsibility of WERFENLIFE, S.A., for the purpose of maintaining the commercial relationship (order management and / or billing, sending product notices, managing business relationships, including conducting surveys, prospecting, statistical analysis and other activities related to the management of business visits), as well as to provide by any means (electronic or not), information about our products and / or services that may be of interest to you.


Responsible for the treatment: WERFENLIFE, S.A., with address at Plaza Europa, 21-23 - 08908 L'Hospitalet de Llobregat (Barcelona). CIF: A08754111
Data Protection Officer: DPO@werfen.com



Legal basis of the treatment: The treatment is necessary for the execution of a commercial contract of product and / or service; and your consent - with respect to commercial communications, supply of products and / or services, market research and improvement of our website.


Recipients or categories of recipients: Werfen companies and third parties to which WERFENLIFE, S.A. has entrusted the provision of services (hosting, training and communication services, organization of events). When legally or contractually required.


Term of conservation: While you are a user of our products and / or services and / or of our web page and whenever you have not opposed receiving commercial communications. Subsequently, the data will be maintained, duly blocked, for a period of 5 years.


Rights: You can exercise the rights of access, rectification or deletion, as well as request to limit your data processing, oppose it, request the portability of your data, or revoke the consent given by writing to DPO@werfen.com


Likewise, the data subject is entitled to lodge a complaint with the Spanish Data Protection Agency www.agpd.es – C/ Jorge Juan, 6 in Madrid
The information you are sending us via this “Contact Us” form will be used for the sole purpose of responding to your request and, therefore, this may be transferred to other Werfen companies or subsidiaries in other countries.
By clicking “I accept”, you agree that your data will be governed by our Data Protection Policy

-------

数据保护政策:根据个人数据保护法规,您会知晓您的个人数据会通过WERFENLIFE,SA进行保存于处理,以便开展正常的商业行为(订单管理或计费),发送产品通知,管理业务关系——包括进行调研、统计、分析和与相关的商务其他活动,以及通过适当方式(电子或非电子)提供有关我们产品的信息或您可能感兴趣的服务。



条款负责人:WERFENLIFE, S.A., 地址:Plaza Europa,21-23 - 08908 L'Hospitalet de Llobregat(巴塞罗那)。CIF:A08754111
数据保护邮箱:DPO@werfen.com


条款的法律依据:您对于本条款的认可以及该条款对于执行处理商品或服务的商业行为是必要的 —— 涉及商业沟通,产品或服务的供应,市场研究和我们网站的改进。


收件人或收件人类别:Werfen公司和WERFENLIFE,S.A。在合法及合理情况下,委托提供服务的第三方(托管,培训和通信服务,活动组织)。


保护期限:当您是我们产品、服务或网页的用户时,以及您同意接收我们的相关商业讯息。数据备份为期5年。


权利:您可以行使访问、纠正或删除的权利,请求限制您的数据,反对、或撤销您的信息。如有需求,请联系DPO@werfen.com


同样,数据主体有权向西班牙数据保护局www.agpd.es提交投诉 ——地址:
C/ Jorge Juan, 6 in Madrid。
您通过“联系我们”表单发送给我们的信息仅用于回复您的请求,因此可能会转移到沃芬其他国家的公司或相关分公司。
点击“我接受”即表示您同意我们的数据受我们的数据保护政策的约束


*本文件以中英文两种语言表述,若有歧义,以英文版本为准。